BioNTech’s $1.25 billion acquisition of CureVac resolves ongoing mRNA patent disputes and strengthens its oncology pipeline. The all-stock deal provides BioNTech with CureVac’s cutting-edge manufacturing infrastructure and research capabilities in Germany, positioning BioNTech as a more integrated immunotherapy leader focused on developing novel cancer treatments.